Alere, Inc. (ALR)
Q1 2012 Earnings Conference Call
April 30, 2012, 08:30 a.m. ET
Doug Guarino - Director, Corporate Relations
Ron Zwanziger - Chairman and CEO
David Teitel - CFO
Dan Leonard - Leerink Swann
John Putnam - Capstone Investments
Greg Simpson - Wunderlich Securities
Eric Criscuolo - Mizuho Securities
Zarak Khurshid - Wedbush Securities
Jeff Frelick - Canaccord Genuity
Jeff - Goldman Sachs
Nicholas Jansen - Raymond James
Good morning and welcome to the Alere Inc. Conference Call to discuss First Quarter 2012 Results. All participants will be in listen-only mode. (Operator Instructions) Please note this event is being recorded.
I’d now like to turn the conference over to Mr. Doug Guarino, Director of Corporate Relations. Please go ahead sir.
Thank you, Denise, and good morning and welcome to the Alere conference call to discuss our results for the quarter ended March 31, 2012. We are joined today by Ron Zwanziger, Chairman and CEO; and David Teitel, CFO.
Before we get to that discussion I’d first like to draw your attention to the fact that certain matters discussed in this conference call will constitute forward-looking statements within the meaning of the U.S. Securities laws. These statements reflect our current view of the respected future events or financial performance and are based on management’s current assumptions and information currently available.
Actual results and the timing of certain events could differ materially from those projected or contemplated by the forward-looking statements due to numerous factors including without limitation our ability to successfully acquire and integrate our acquisitions and to recognize the expected benefit that restructuring and new business activities. Our exposure to changes in interest rates and foreign currency exchange rates; our ability to successfully develop and commercialize products, the market acceptance of our products; continued acceptance of Health Management services by payers, providers and patients; our ability to develop enhanced Health Management programs through the integrated use of innovative diagnostic and monitoring devices and to recognize the expected benefits of this strategy; the impact of healthcare reform legislation as well as future reform initiative; the content and timing of regulatory decisions and actions including the results of FDA inspections as well as the impact of changes in reimbursement policy and budgetary constraint, both in the United States and abroad. The effective pending and future legal proceedings and our financial performance, and the risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission including our From 10-K for the year ended December 31, 2011 as well as in our quarterly reports on Form 10-Q.